Vanguard Portfolio Management
RYTM icon

Vanguard Portfolio Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Vanguard Portfolio Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$300M Buy
3,148,914
+12,019
+0.4% +$1.28M 0.01% 935
2026
Q2 		$348M Buy
3,136,895
+96,177
+3% +$8.7M 0.02% 902
2026
Q1 		$264M Buy
+3,040,718
New +$296M 0.01% 974

Other funds holding RYTM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $442M AUM 36.72% 1-Year Est. Return

Vanguard Portfolio Management's RYTM Position: Q3 2026 in Review

Vanguard Portfolio Management increased its Rhythm Pharmaceuticals (RYTM) stake by 0.38% in Q3 2026, buying an estimated $1.28M and bringing the position to 3,148,914 shares worth $300M. The position accounts for 0.01% of the portfolio, ranked #935.

Vanguard Portfolio Management first reported a position in RYTM in Q1 2026 and has held it in 3 quarters since. The position peaked at $348M in Q2 2026. 239 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • Vanguard Portfolio Management held 3,148,914 shares of Rhythm Pharmaceuticals worth $300M as of Q3 2026.
  • Vanguard Portfolio Management bought 12,019 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $1.28M.
  • Rhythm Pharmaceuticals made up 0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #935 holding.
  • Vanguard Portfolio Management first reported a position in Rhythm Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Portfolio Management's Rhythm Pharmaceuticals position peaked at $348M in Q2 2026.
  • 239 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.